Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 42 % of short-term debt in 2025; threshold 65 %.
-
Shrinking team NBB
FTE fell two years in a row, from 97.6 to 80.6.
Financials
Financial year 2025
DIDAK INJECTION from Grobbendonk, company number BE0428125831, closed financial year 2025 with a result of € 2.3 million after tax. For that financial year DIDAK INJECTION recorded revenue of € 43.5 million and equity of € 14.4 million. Compared with financial year 2024, the result moved from € 2.1 million to € 2.3 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.
€ 14.4 million
▲ 8% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 2.3 million
▲ 8% vs 2024
Profit after tax over the fiscal year.
€ 226,769
▼ 65% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 1.2 million paid out
52 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
80.6
▼ 6.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 5.6 million
▼ 9% vs 2024
€ 70,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 704,301
▲ 3% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 5.2 million
▼ 19% vs 2024
Loans from banks and other lenders, long and short.
€ 4.4 million
▲ 20% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 47 days on average.
€ 865,317
▼ 16% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 60,158,109 | € 44,253,079 | € 39,178,519 | € 43,493,346 | ▲ 11% |
| Profit after taxes | € 3,081,062 | € 2,650,028 | € 2,143,084 | € 2,304,084 | ▲ 8% |
| Equity | € 12,991,662 | € 12,641,690 | € 13,284,773 | € 14,388,858 | ▲ 8% |
| Total debts | € 10,485,933 | € 11,805,827 | € 11,575,665 | € 10,751,641 | ▼ 7% |
| Cash | € 473,368 | € 417,221 | € 657,157 | € 226,769 | ▼ 65% |
| Land & buildings | € 2,753,761 | € 2,466,685 | € 2,232,321 | € 2,009,937 | ▼ 10% |
| Retained profit | € 12,418,662 | € 12,068,690 | € 12,711,773 | € 13,815,858 | ▲ 9% |
| Dividend | € 4,500,000 | € 3,000,000 | € 1,500,000 | € 1,200,000 | ▼ 20% |
| Bank debt | € 4,734,286 | € 6,240,000 | € 6,412,857 | € 5,200,000 | ▼ 19% |
| Balance sheet total | € 23,515,094 | € 24,557,517 | € 24,970,438 | € 25,250,499 | ▲ 1% |
| Employees (FTE) | 100.7 | 97.6 | 87 | 80.6 | ▼ 6.4 |
Key figures of DIDAK INJECTION, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to DIDAK INJECTION?
What happened at DIDAK INJECTION in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- SALDEC stepped down as director. NBB
- VANDEPUTTE-VALCKE stepped down as director. NBB
- DYNAMIC VOF stepped down as director. NBB
- ECNOEL stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 2.3 million (▲ 8% vs 2024). Source: NBB ↗
- VANDEPUTTE-VALCKE became a director. NBB
- DYNAMIC VOF became a director. NBB
- ECNOEL became a director. NBB
In short
From € 3.1 million profit in 2022 to € 2.3 million profit in 2025.
Paid € 3.4 million in corporate taxes since 2022.
Best year ever: 2022, with € 3.1 million profit.
Paid out € 10.2 million in dividends to the owners in total.
Management
The stake of VANDEPUTTE - VALCKE, HUNTER EN COLMAN comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
DIDAK INJECTIONThe shares are held by VANDEPUTTE - VALCKE (33.4%) and HUNTER EN COLMAN (33.3%).
Directors
According to the 2025 annual accounts
Director · represented by Arnold Deceuninck, Alexander DECEUNINCK
Also active at: Edero, ECNOEL, Reyes Holding, LOXXER, PLUVIO, Zystm, LOGICAL-SYSTEMS, LETOPLAST INVEST
since 2020 · until 2030
since 2024 · until 2030
since 2024 · until 2030
Managing director · represented by Alexander Deceuninck
Also active at: ANZIPLAST, HUNTER EN COLMAN, CASIER TRADING, ALCAPLAST
since 2024 · until 2030
Shareholders
33.4%
33.3%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Industrieweg 1
2280 Grobbendonk
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0428.125.831
- VAT number
- BE 0428.125.831
- Registered office
- Industrieweg 1, 2280 Grobbendonk
- Names & denominations
- DIDAK INJECTION
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 2 January 1986
- Peppol
- Active · Active since 5 Jan 2026
- Activities · NACE
Vervaardiging van verpakkingsmateriaal van kunststof
Vervaardiging van andere producten van kunststof
Vervaardiging van overige producten van kunststof